Developer docs
API playgroundTry for free, no card

Search company profiles

iFast Diagnostics

Full company profile

uuid0002hma

Namestring
iFast Diagnostics
Legal namestring
iFAST Diagnostics Limited
Company typeenum
Private
Founded yearint
2023
Descriptiontext

iFast Diagnostics Limited is a UK-based in-vitro diagnostics company founded in 2023 as a University of Southampton spinout, developing the iFAST ONE ultra-rapid antimicrobial susceptibility testing (AST) platform. The technology is built on microfluidic impedance cytometry: bacteria suspended in solution are exposed to antibiotics, incubated for two hours, and then measured at single-cell resolution on a microfluidic impedance chip (approximately 5,000 bacteria per sample, read in roughly 30 seconds per well). The instrument produces both qualitative Resistant/Susceptible outputs and quantitative Minimum Inhibitory Concentration (MIC) results for up to 16 drugs on the Gram-Negative UK panel in under 3 hours, compared with a standard 40-hour (or 24–72 hour) growth-based workflow.

The company monetises via capital sales of the iFAST ONE instrument plus recurring per-sample economics (from £30 per sample, positioned as cost-equivalent to or cheaper than gold-standard broth microdilution). Its customers span hospital clinical laboratories (NHS and private), commercial diagnostic laboratories (with SYNLAB UK & Ireland as the first commercial laboratory partner), and government/public health agencies (with UK Health Security Agency as the first multi-system commercial customer). UKCA certification covers Gram-negative blood cultures, isolates and quantitative AST for key drugs including Meropenem and Piperacillin-tazobactam; ISO 13485 certification covers design, manufacture and distribution. The company is headquartered in Whiteley, Hampshire, with an additional office on the University of Southampton campus, and had raised £12m of cumulative investment as of May 2026 across funding rounds led by QantX (2023), KHP Ventures (2024) and Meridian Health Ventures (2026), supported by Innovate UK non-dilutive grants and loans.

The go-to-market combines direct enterprise field sales to UK hospital and reference labs with channel-led scale-up via commercial laboratory partners, supported by conference-driven demand generation (FIS International 2025, ESCMID Global 2026) and PR/earned media. Following UK routine clinical availability from early 2026, the company has publicly committed to securing EU regulatory approval and accelerating US FDA clearance, and to expanding the platform's clinical surface area beyond Gram-negative AST into fungal infections and STDs through validation work at UKHSA Porton Down.

Short descriptiontext

iFast Diagnostics is a UK-based diagnostics company whose iFAST ONE platform uses microfluidic impedance cytometry to deliver antimicrobial susceptibility testing results in under 3 hours for hospital labs, commercial diagnostics providers (notably SYNLAB UK & Ireland), and public health agencies (notably UKHSA), targeting the $4bn+ AST market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouthampton, United Kingdom
HQ citystring
Southampton
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial susceptibility testing, rapid diagnostics instruments, microfluidic impedance cytometry, clinical microbiology equipment, antimicrobial resistance solutions
Industry1 code
PRIMARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)
NAICS code2 codes
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Testing Laboratories8734
Product category
Antimicrobial Susceptibility Testing Diagnostics
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Multi-system instrument sales (hardware)
TypeHardware Sales
Description

Capital equipment sales of the iFAST ONE ultra-rapid AST system. UKHSA's first multi-system commercial order (three instruments) indicates a multi-instrument deal structure with enterprise/government customers.

ifastdiagnostics.com
2Per-sample testing (consumables/usage)
TypeUsage Based
Description

Recurring per-sample economics at from £30 per sample, equivalent to or cheaper than current gold standard methods. With up to 10 tests/day per reader, this implies consumable or per-test revenue after instrument placement.

ifastdiagnostics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1From £30 per sample; multi-system instrument quotes on request
ModelUnit PricingBilling cadencePay-as-you-go
Notes

From £30 per sample, equivalent to or cheaper than current gold standard methods. Research and UKCA-approved systems available immediately. Instrument pricing is quote-based via sales@ifastdiagnostics.com.

ifastdiagnostics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1iFAST ONE
Description

Ultra-rapid Antimicrobial Susceptibility Test (AST) system delivering high-throughput AST results to clinicians in under three hours from Gram-negative blood cultures and isolates.

ifastdiagnostics.com
Core offering1 text field

iFast Diagnostics develops and sells the iFAST ONE ultra-rapid antimicrobial susceptibility testing (AST) system, a hardware instrument that uses a proprietary microfluidic impedance cytometry chip to measure electrical properties of individual bacterial cells. After a two-hour incubation, the instrument reads each well in about 30 seconds across roughly 5,000 bacteria per sample, delivering both qualitative Resistant/Susceptible and quantitative Minimum Inhibitory Concentration (MIC) results for up to 16 drugs on the Gram-Neg UK panel in under three hours from Gram-negative positive blood cultures or bacterial isolates, compared with the standard 24–72 hour gold-standard workflow. The company sells capital instruments to hospital, reference and public-health laboratories in Great Britain (UKCA and ISO 13485 certified), with planned EU and US market entry.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • AST results delivered in under 3 hours versus 40+ hours standard (10x faster)
+4 more records
Product overview1 text field

iFast Diagnostics offers a single, unified rapid antimicrobial susceptibility testing (AST) product line built around its microfluidic impedance cytometry core technology. The flagship iFAST platform and the iFAST ONE instrument together deliver resistant/susceptible and Minimum Inhibitory Concentration (MIC) results in under 3 hours from Gram-negative blood cultures and bacterial isolates, addressing a $4bn+ AST market and tackling antimicrobial resistance by enabling clinicians to prescribe the optimal antibiotic within a single working shift. The iFAST ONE instrument is the deployable hardware embodiment of the iFAST microfluidic impedance cytometer technology, and the combined offering has been UKCA Certified for Gram-negative blood cultures and isolates, Quantitative AST (Meropenem, Piperacillin-tazobactam), ISO 13485 certified for design/manufacture/distribution, and adopted by partners including UKHSA (first commercial order) and SYNLAB UK & Ireland (first commercial laboratory partner).

Product and service2 records
1iFAST rapid Antimicrobial Susceptibility Testing (AST) platform
CategoryClinical diagnostics platform
Description

Rapid antimicrobial susceptibility testing (AST) platform based on microfluidic impedance cytometry that delivers Resistant/Susceptible and Minimum Inhibitory Concentration (MIC) results for up to 16 drugs per sample (Gram-Neg UK panel) in under three hours from Gram-negative positive blood cultures or bacterial isolates, compared with the standard 24–72 hour gold-standard process. For hospital, reference and public-health laboratories.

2iFAST ONE ultra-rapid AST system
CategoryClinical diagnostics instrument / hardware system
Description

Ultra-rapid AST hardware instrument using a microfluidic impedance chip to measure electrical properties of single bacteria at high speed. Provides qualitative Resistant/Susceptible and quantitative MIC results for up to 16 drugs per sample in under three hours; UKCA certified for Gram-negative blood cultures, Gram-negative isolates and Quantitative AST, and ISO 13485 certified. Multi-system commercial sales began with the UKHSA order in December 2025.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

iFAST's first commercial laboratory partner. Builds on a pre-2023 research collaboration. Focus on integrating rapid AST into SYNLAB laboratory workflows, generating evidence for NHS decision-makers, and rolling out the iFAST ONE AST system for routine clinical use alongside ongoing SPS research evaluation.

2UK Health Security Agency (UKHSA)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Long-standing research partner since iFAST was founded in early 2023; UKHSA first used a prototype iFAST instrument under an NIHR-funded research partnership with the University of Southampton. Converted to a commercial relationship with the first multi-system order (three iFAST Rapid AST systems) for UKHSA Porton Down's Countermeasure Development Evaluation and Preparedness Division labs.

ifastdiagnostics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

iFAST Diagnostics is a spinout from the University of Southampton founded in early 2023, based on research led by founders Prof Hywel Morgan and Dr Daniel Spencer. The original prototype development and NIHR-funded research partnership with UKHSA originated here.

4Southwest Pathology Services (SPS)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research evaluation partner running the iFAST system research evaluation in parallel with the SYNLAB commercial rollout.

ifastdiagnostics.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

iFAST was selected to join the Healthcare Innovation Consortium's AMR Innovation Programme alongside five other companies addressing antimicrobial resistance, receiving support to commercialise and scale its work.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1OpGen
TypeEmerging player
Description

Develops rapid molecular diagnostics for AMR including the Acuitas AMR Gene Panel and AST prediction; an adjacent emerging player combining rapid ID with predicted susceptibility, complementary to phenotypic AST platforms like iFAST.

2Beckman Coulter
TypeBroad incumbent
Description

Offers the MicroScan WalkAway AST system and is part of Danaher, a large installed base in clinical microbiology labs; a comparable incumbent with overlapping AST instrumentation and panel offerings.

TypeBroad incumbent
Description

Major diagnostics incumbent with the BD Phoenix M50 AST system and broad microbiology portfolio; competes head-to-head with iFAST for hospital lab AST budgets and KOL relationships.

TypeBroad incumbent
Description

Global leader in clinical microbiology with the VITEK 2 and VITEK MS platforms; the dominant incumbent in hospital AST workflows that iFAST is targeting with a faster, growth-independent method.

TypeEmerging player
Description

Developer of T2 Magnetic Resonance-based rapid diagnostics for sepsis-relevant pathogens; an emerging player in the same clinical-decision-point rapid diagnostics category though its technology is molecular-detection rather than AST.

TypeDirect peer
Description

US-based rapid AST company developing next-generation phenotypic AST platforms intended to deliver same-day antibiotic susceptibility results; directly comparable mission and technology class to iFAST.

TypeDirect peer
Description

Swedish developer of the ASTar rapid AST system that delivers phenotypic AST directly from positive blood cultures in hours; the most directly comparable rapid-AST pure-play competing for the same sepsis/AST use case as iFAST.

8Affordable Diagnostics / Zone Diagnostics-type rapid ID-AST
TypeEmerging player
Description

Emerging rapid AST and ID-AST startups and academic spinouts (e.g. Affinity Biosensors, GeneFluidics) that compete for the same AMR/sepsis testing opportunity with novel microfluidics or molecular approaches.

TypeDirect peer
Description

Developer of a rapid phenotypic AST platform based on sensing volatile metabolites; a direct peer pursuing the same rapid-AST-from-blood-culture opportunity with a different underlying detection chemistry.

TypeDirect peer
Description

Developer of the Accelerate Pheno system, one of the first FDA-cleared rapid phenotypic AST platforms delivering results from positive blood cultures in hours; a direct commercial comparator to iFAST in the rapid AST category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iFast Diagnostics

Antimicrobial Susceptibility Testing Diagnosticsifastdiagnostics.com

iFast Diagnostics is a UK-based diagnostics company whose iFAST ONE platform uses microfluidic impedance cytometry to deliver antimicrobial susceptibility testing results in under 3 hours for hospital labs, commercial diagnostics providers (notably SYNLAB UK & Ireland), and public health agencies (notably UKHSA), targeting the $4bn+ AST market.

What iFast Diagnostics does

iFast Diagnostics Limited is a UK-based in-vitro diagnostics company founded in 2023 as a University of Southampton spinout, developing the iFAST ONE ultra-rapid antimicrobial susceptibility testing (AST) platform. The technology is built on microfluidic impedance cytometry: bacteria suspended in solution are exposed to antibiotics, incubated for two hours, and then measured at single-cell resolution on a microfluidic impedance chip (approximately 5,000 bacteria per sample, read in roughly 30 seconds per well). The instrument produces both qualitative Resistant/Susceptible outputs and quantitative Minimum Inhibitory Concentration (MIC) results for up to 16 drugs on the Gram-Negative UK panel in under 3 hours, compared with a standard 40-hour (or 24–72 hour) growth-based workflow.

The company monetises via capital sales of the iFAST ONE instrument plus recurring per-sample economics (from £30 per sample, positioned as cost-equivalent to or cheaper than gold-standard broth microdilution). Its customers span hospital clinical laboratories (NHS and private), commercial diagnostic laboratories (with SYNLAB UK & Ireland as the first commercial laboratory partner), and government/public health agencies (with UK Health Security Agency as the first multi-system commercial customer). UKCA certification covers Gram-negative blood cultures, isolates and quantitative AST for key drugs including Meropenem and Piperacillin-tazobactam; ISO 13485 certification covers design, manufacture and distribution. The company is headquartered in Whiteley, Hampshire, with an additional office on the University of Southampton campus, and had raised £12m of cumulative investment as of May 2026 across funding rounds led by QantX (2023), KHP Ventures (2024) and Meridian Health Ventures (2026), supported by Innovate UK non-dilutive grants and loans.

The go-to-market combines direct enterprise field sales to UK hospital and reference labs with channel-led scale-up via commercial laboratory partners, supported by conference-driven demand generation (FIS International 2025, ESCMID Global 2026) and PR/earned media. Following UK routine clinical availability from early 2026, the company has publicly committed to securing EU regulatory approval and accelerating US FDA clearance, and to expanding the platform's clinical surface area beyond Gram-negative AST into fungal infections and STDs through validation work at UKHSA Porton Down.

iFast Diagnostics firmographics

Firmographics
Name
iFast Diagnostics
Legal name
iFAST Diagnostics Limited
Website
https://ifastdiagnostics.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
iFast Diagnostics is a UK-based diagnostics company whose iFAST ONE platform uses microfluidic impedance cytometry to deliver antimicrobial susceptibility testing results in under 3 hours for hospital labs, commercial diagnostics providers (notably SYNLAB UK & Ireland), and public health agencies (notably UKHSA), targeting the $4bn+ AST market.
Ownership category
akta.pro rank

iFast Diagnostics industry classification

Industry
Product category
Antimicrobial Susceptibility Testing Diagnostics
NAICS
Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)

Keywords

  • Antimicrobial susceptibility testing
  • Rapid diagnostics instruments
  • Microfluidic impedance cytometry
  • Clinical microbiology equipment
  • Antimicrobial resistance solutions

Where iFast Diagnostics is headquartered

Location

Headquarters

HQ city
Southampton
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

iFast Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Multi-system instrument sales (hardware): Capital equipment sales of the iFAST ONE ultra-rapid AST system. UKHSA's first multi-system commercial order (three instruments) indicates a multi-instrument deal structure with enterprise/government customers.
  2. Per-sample testing (consumables/usage): Recurring per-sample economics at from £30 per sample, equivalent to or cheaper than current gold standard methods. With up to 10 tests/day per reader, this implies consumable or per-test revenue after instrument placement.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goFrom £30 per sample; multi-system instrument quotes on request

Go-to-market motion4 records

Distribution channels3 records

Marketing channels5 records

iFast Diagnostics product offering

Product offering

Core offering

iFast Diagnostics develops and sells the iFAST ONE ultra-rapid antimicrobial susceptibility testing (AST) system, a hardware instrument that uses a proprietary microfluidic impedance cytometry chip to measure electrical properties of individual bacterial cells. After a two-hour incubation, the instrument reads each well in about 30 seconds across roughly 5,000 bacteria per sample, delivering both qualitative Resistant/Susceptible and quantitative Minimum Inhibitory Concentration (MIC) results for up to 16 drugs on the Gram-Neg UK panel in under three hours from Gram-negative positive blood cultures or bacterial isolates, compared with the standard 24–72 hour gold-standard workflow. The company sells capital instruments to hospital, reference and public-health laboratories in Great Britain (UKCA and ISO 13485 certified), with planned EU and US market entry.

Product overview

iFast Diagnostics offers a single, unified rapid antimicrobial susceptibility testing (AST) product line built around its microfluidic impedance cytometry core technology. The flagship iFAST platform and the iFAST ONE instrument together deliver resistant/susceptible and Minimum Inhibitory Concentration (MIC) results in under 3 hours from Gram-negative blood cultures and bacterial isolates, addressing a $4bn+ AST market and tackling antimicrobial resistance by enabling clinicians to prescribe the optimal antibiotic within a single working shift. The iFAST ONE instrument is the deployable hardware embodiment of the iFAST microfluidic impedance cytometer technology, and the combined offering has been UKCA Certified for Gram-negative blood cultures and isolates, Quantitative AST (Meropenem, Piperacillin-tazobactam), ISO 13485 certified for design/manufacture/distribution, and adopted by partners including UKHSA (first commercial order) and SYNLAB UK & Ireland (first commercial laboratory partner).

Differentiator

Problem solved

Functional benefit

Brands

  • iFAST ONE: Ultra-rapid Antimicrobial Susceptibility Test (AST) system delivering high-throughput AST results to clinicians in under three hours from Gram-negative blood cultures and isolates.

Products and services

  • iFAST rapid Antimicrobial Susceptibility Testing (AST) platform Rapid antimicrobial susceptibility testing (AST) platform based on microfluidic impedance cytometry that delivers Resistant/Susceptible and Minimum Inhibitory Concentration (MIC) results for up to 16 drugs per sample (Gram-Neg UK panel) in under three hours from Gram-negative positive blood cultures or bacterial isolates, compared with the standard 24–72 hour gold-standard process. For hospital, reference and public-health laboratories.
  • iFAST ONE ultra-rapid AST system Ultra-rapid AST hardware instrument using a microfluidic impedance chip to measure electrical properties of single bacteria at high speed. Provides qualitative Resistant/Susceptible and quantitative MIC results for up to 16 drugs per sample in under three hours; UKCA certified for Gram-negative blood cultures, Gram-negative isolates and Quantitative AST, and ISO 13485 certified. Multi-system commercial sales began with the UKHSA order in December 2025.

Quantifiable outcome

  • AST results delivered in under 3 hours versus 40+ hours standard (10x faster)
  • +4 more outcomes

Companies that use iFast Diagnostics

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

iFast Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

iFast Diagnostics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered flagship, core and minor.

  • SYNLAB UK & IrelandflagshipStrategic or Co-development Partner · 1 May 2026iFAST's first commercial laboratory partner. Builds on a pre-2023 research collaboration. Focus on integrating rapid AST into SYNLAB laboratory workflows, generating evidence for NHS decision-makers, and rolling out the iFAST ONE AST system for routine clinical use alongside ongoing SPS research evaluation.
  • UK Health Security Agency (UKHSA)flagshipStrategic or Co-development Partner · 1 December 2025Long-standing research partner since iFAST was founded in early 2023; UKHSA first used a prototype iFAST instrument under an NIHR-funded research partnership with the University of Southampton. Converted to a commercial relationship with the first multi-system order (three iFAST Rapid AST systems) for UKHSA Porton Down's Countermeasure Development Evaluation and Preparedness Division labs.
  • University of SouthamptoncoreStrategic or Co-development Partner · 1 January 2023iFAST Diagnostics is a spinout from the University of Southampton founded in early 2023, based on research led by founders Prof Hywel Morgan and Dr Daniel Spencer. The original prototype development and NIHR-funded research partnership with UKHSA originated here.
  • Southwest Pathology Services (SPS)minorStrategic or Co-development PartnerResearch evaluation partner running the iFAST system research evaluation in parallel with the SYNLAB commercial rollout.
  • Healthcare Innovation ConsortiumminorGTM or Marketing PartneriFAST was selected to join the Healthcare Innovation Consortium's AMR Innovation Programme alongside five other companies addressing antimicrobial resistance, receiving support to commercialise and scale its work.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

iFast Diagnostics competitors and assessment

Company assessment

Emerging players

  • OpGen: Develops rapid molecular diagnostics for AMR including the Acuitas AMR Gene Panel and AST prediction; an adjacent emerging player combining rapid ID with predicted susceptibility, complementary to phenotypic AST platforms like iFAST.
  • T2 Biosystems: Developer of T2 Magnetic Resonance-based rapid diagnostics for sepsis-relevant pathogens; an emerging player in the same clinical-decision-point rapid diagnostics category though its technology is molecular-detection rather than AST.
  • Affordable Diagnostics / Zone Diagnostics-type rapid ID-AST: Emerging rapid AST and ID-AST startups and academic spinouts (e.g. Affinity Biosensors, GeneFluidics) that compete for the same AMR/sepsis testing opportunity with novel microfluidics or molecular approaches.

Broad incumbents

  • Beckman Coulter: Offers the MicroScan WalkAway AST system and is part of Danaher, a large installed base in clinical microbiology labs; a comparable incumbent with overlapping AST instrumentation and panel offerings.
  • Becton, Dickinson and Company (BD): Major diagnostics incumbent with the BD Phoenix M50 AST system and broad microbiology portfolio; competes head-to-head with iFAST for hospital lab AST budgets and KOL relationships.
  • bioMérieux: Global leader in clinical microbiology with the VITEK 2 and VITEK MS platforms; the dominant incumbent in hospital AST workflows that iFAST is targeting with a faster, growth-independent method.

Direct peers

  • Selux Diagnostics: US-based rapid AST company developing next-generation phenotypic AST platforms intended to deliver same-day antibiotic susceptibility results; directly comparable mission and technology class to iFAST.
  • Q-Linea AB: Swedish developer of the ASTar rapid AST system that delivers phenotypic AST directly from positive blood cultures in hours; the most directly comparable rapid-AST pure-play competing for the same sepsis/AST use case as iFAST.
  • Specific Diagnostics: Developer of a rapid phenotypic AST platform based on sensing volatile metabolites; a direct peer pursuing the same rapid-AST-from-blood-culture opportunity with a different underlying detection chemistry.
  • Accelerate Diagnostics: Developer of the Accelerate Pheno system, one of the first FDA-cleared rapid phenotypic AST platforms delivering results from positive blood cultures in hours; a direct commercial comparator to iFAST in the rapid AST category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

iFast Diagnostics social profiles

Digital presence

iFast Diagnostics compliance and trust

Trust signal

Compliance5 records

iFast Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iFast Diagnostics leadership team

Management profile

Number of profiles

Profiles4 records

iFast Diagnostics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iFast Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iFast Diagnostics

What does iFast Diagnostics do?

iFast Diagnostics develops and sells the iFAST ONE ultra-rapid antimicrobial susceptibility testing (AST) system, a hardware instrument that uses a proprietary microfluidic impedance cytometry chip to measure electrical properties of individual bacterial cells. After a two-hour incubation, the instrument reads each well in about 30 seconds across roughly 5,000 bacteria per sample, delivering both qualitative Resistant/Susceptible and quantitative Minimum Inhibitory Concentration (MIC) results for up to 16 drugs on the Gram-Neg UK panel in under three hours from Gram-negative positive blood cultures or bacterial isolates, compared with the standard 24–72 hour gold-standard workflow. The company sells capital instruments to hospital, reference and public-health laboratories in Great Britain (UKCA and ISO 13485 certified), with planned EU and US market entry.

Is iFast Diagnostics a public or private company?

iFast Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was iFast Diagnostics founded?

iFast Diagnostics was founded in 2023. It employs 11 to 50 people.

Where is iFast Diagnostics based?

iFast Diagnostics is headquartered in Southampton, United Kingdom, in the Europe region.

How does iFast Diagnostics make money?

Two revenue lines are on record. Multi-system instrument sales (hardware) is the primary driver. The others are per-sample testing (consumables/usage).

Who are iFast Diagnostics's main competitors?

Emerging players on record are OpGen, T2 Biosystems and Affordable Diagnostics / Zone Diagnostics-type rapid ID-AST. Broad incumbents are Beckman Coulter, Becton, Dickinson and Company (BD) and bioMérieux. Direct peers are Selux Diagnostics, Q-Linea AB, Specific Diagnostics and Accelerate Diagnostics.

Does iFast Diagnostics have an API?

No public API is recorded for iFast Diagnostics.

What industry is iFast Diagnostics in?

iFast Diagnostics's product category is Antimicrobial Susceptibility Testing Diagnostics. Its primary akta.pro industry code is HLAGADAA, Bioanalytical Testing (PK/ADA/NAb). Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InsidermediaiFAST Diagnostics raises £5m as it looks to secure EU and US approvalSouthampton-based iFAST Diagnostics, a company developing rapid antimicrobial susceptibility testing technology, has closed an oversubscribed £5m funding round led by Meridian Health Ventures with participation from existing investors QantX, RAW Ventures, OKG Capital, and Cambridge Capital Group, alongside £2.1m in non-dilutive Innovate UK loan funding. The capital will support UK market expansion, EU regulatory approval, and accelerate the clinical and regulatory programme for US FDA clearance. The latest raise values the company at nearly five times its previous valuation 18 months ago, bringing total investment to £12m.Tech.euiFAST Diagnostics bags £5M to speed up infection testing and tackle antimicrobial resistanceiFAST Diagnostics closed a £5 million funding round led by Meridian Health Ventures, valuing the company at nearly five times its previous valuation. The rapid antimicrobial susceptibility testing platform delivers results in under three hours, and the funding will support UK rollout, EU approval, and US FDA clearance.Innovation News NetworkCombatting AMR by optimising antibiotic therapy timelinesiFAST Diagnostics Ltd has developed a microfluidic impedance cytometer technology that rapidly delivers antimicrobial susceptibility testing results within three hours, significantly faster than traditional methods. This innovation aims to improve patient outcomes, reduce antimicrobial resistance, and enhance operational efficiency in clinical laboratories. The technology is validated, certified, and available in Great Britain, with plans for EU expansion.InsidermediaDiagnostics company secures £5m to bring pioneering medical technology to marketiFAST, a Southampton-based diagnostics company, closed a £5m seed round led by KHP Ventures. Its technology tests bacteria to identify effective antibiotics in under three hours, versus the current 48-72 hours. The UK launch is planned for early 2025, with US and EU follow-ups.UKI2SiFAST Diagnostics raise £2M to track and treat antibiotic-resistant bugs – UKI2SiFAST Diagnostics has raised £2 million in funding to commercialize its rapid diagnostic platform for identifying antibiotic-resistant bacteria. The investment, led by QantX and supported by KHP Ventures and UKI2S, will enable the company to productize the technology and achieve first sales next year. This development aims to reduce the time required for antimicrobial susceptibility testing from days to hours, addressing a critical global health challenge.QantxiFAST Diagnostics raise £2M to track and treat antibiotic-resistant bugsiFAST Diagnostics has raised £2 million in funding led by QantX to commercialize its rapid diagnostic platform for identifying antibiotic-resistant bacteria. The technology, developed at the University of Southampton and validated with the UK Health Security Agency, reduces testing time from 48-72 hours to a few hours, enabling faster clinical intervention. This investment will support productization and initial sales to biotech firms aiming to develop more effective antibiotics.